Corporate
Gossamer Bio Stock Crashes 78% as Seralutinib Narrowly Misses Phase 3 Endpoint, Still Eyes FDA Path
4d ago
You're signed outSign in or to get full access.
Gossamer Bio Inc (GOSS) Earnings Call Transcripts
Browse quarterly earnings call transcripts for Gossamer Bio Inc.